Oric Pharmaceuticals News

Express News | Oric Pharmaceuticals Inc - Expect to Report Updated Phase 1B Data in First Half of 2025

Moomoo 24/7Apr 15 16:15 ET

Express News | Oric Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1B Trial of Oric-114 in Patients With Mutated Nsclc

Moomoo 24/7Apr 15 16:15 ET

Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Omeros (OMER) and Urogen Pharma (URGN)

TipRanksApr 9 07:40 ET

ORIC Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of

GlobeNewswireApr 5 16:30 ET

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of

GlobeNewswireApr 4 16:30 ET

Oric Pharmaceuticals Bolsters Incentive Plan to Attract Talent

TipRanksMar 29 16:33 ET

Oric Pharmaceuticals Is Maintained at Overweight by JP Morgan

Oric Pharmaceuticals Is Maintained at Overweight by JP Morgan

Dow JonesMar 27 10:51 ET

JP Morgan Maintains Overweight on ORIC Pharmaceuticals, Lowers Price Target to $18

JP Morgan analyst Anupam Rama maintains ORIC Pharmaceuticals with a Overweight and lowers the price target from $19 to $18.

Analyst UpgradesMar 27 10:40 ET

Micron To Rally Around 134%? Here Are 10 Top Analyst Forecasts For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Rosenblatt

BenzingaMar 21 09:15 ET

Oric Pharmaceuticals: Sustained Buy Rating Amid Strong Financials and Upcoming Catalysts

TipRanksMar 21 06:27 ET

Oric Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Oric Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMar 21 06:25 ET

Express News | HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $21

Moomoo 24/7Mar 21 06:15 ET

ORIC Pharmaceuticals Inc (ORIC) Reports Q4 and Full Year 2023 Financial Results

Yahoo FinanceMar 12 21:01 ET

These Analysts Revise Their Forecasts On ORIC Pharmaceuticals After Q4 Results

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) reported a loss for the fourth quarter on Monday. ORIC Pharmaceuticals posted a quarterly loss of 49 cents per share, in-line with market estimates, according

BenzingaMar 12 12:55 ET

ORIC Pharmaceuticals Stock Target Raised to $17 on Strong Prospects

InvestingMar 12 10:04 ET

Oric Pharmaceuticals Price Target Maintained With a $20.00/Share by Wedbush

Oric Pharmaceuticals Price Target Maintained With a $20.00/Share by Wedbush

Dow JonesMar 12 08:32 ET

Analysts Conflicted on These Healthcare Names: Insmed (INSM), Oric Pharmaceuticals (ORIC) and CytomX Therapeutics (CTMX)

TipRanksMar 12 08:20 ET

Oric Pharmaceuticals Is Maintained at Outperform by Baird

Oric Pharmaceuticals Is Maintained at Outperform by Baird

Dow JonesMar 12 08:16 ET

Express News | Baird Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $25

Moomoo 24/7Mar 12 08:06 ET

ORIC Pharmaceuticals Files for Automatic Mixed Securities Shelf

Seeking AlphaMar 11 17:34 ET